

October 1, 2020
SanBio Co., Ltd.

Hiroyasu Narita Joins SanBio as the Head of Clinical Development

The SanBio Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) hereby announces that Hiroyasu Narita has joined the Group as the Head of Clinical Development of SanBio Co., Ltd. (hereafter the “Company”) as of October 1, 2020.

After joining Lederle Japan (current Pfizer) as a pharmacology researcher at Lederle’s biological research center, Mr. Narita worked at a number of prominent pharmaceutical companies including GlaxoSmithKline and Novartis, where he was in charge of clinical development primarily in the area of central nervous system disorders. He has led many pharmaceutical drugs that are being marketed around the world even to this day to obtaining approval in Japan. Before joining the Company, he served as the Head, Senior Director, Japan Development Center at Lundbeck Japan. As such, he is a leading scientist with a wealth of experience and track record in clinical development in the field of central nervous system disorders. Mr. Narita holds a PhD in Neurophysiology from Toho University Graduate School of Medicine.

Currently, the SanBio Group is preparing to launch SB623 for the treatment of chronic effects resulting from traumatic brain injury in Japan before it does so anywhere else in the world while also making progress in its global development. Further, the Group is working toward commencing clinical trials of SB623 in the ischemic stroke and hemorrhagic stroke programs in Japan. Mr. Narita, in collaboration with key opinion leaders in the field of central nervous system disorders, stem cell research, and regenerative medicine, will lead the Company’s overall clinical development operations in Japan. At the same time, he will work alongside Chief Medical Officer Bijan Nejadnik, M.D. to play an important role in formulating clinical development strategies for each development program as well as long-term strategies for the Group.

Mr. Narita commented as below on his joining the Company:

“I am very excited to have been given this opportunity to participate in the clinical development of regenerative medicine, a whole new field, and at the same time feel a great sense of responsibility in bringing SanBio’s pipeline products to market. As SanBio works toward its goal of maximizing the value of SB623, I hope my thirty-something years of experience in pharmaceutical development targeting central nervous system disorders will help make a contribution.”

Keita Mori, Representative Director and President of the Company made the following comment:

“I am thrilled to have on board Mr. Narita, who has many years of experience and extensive track record in pharmaceutical development. Under the leadership of Mr. Narita, we at SanBio will do our utmost to

strengthen our R&D structure and deliver SB623 to patients suffering from chronic motor deficit caused by traumatic brain injury, ischemic stroke, or hemorrhagic stroke as soon as possible.”

About SanBio Co., Ltd. and SanBio, Inc.

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company’s propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at <https://sanbio.com>.

For more information, contact:

SanBio Co., Ltd.

Management Administration

info@sanbio.jp